Topical bio(in)equivalence of metronidazole formulations in vivo by Pedon de Araujo, Thalita et al.
        
Citation for published version:
Pedon de Araujo, T, Moura Fittipaldi, I, Galindo Bedor, DC, Ludna Duarte, M, Cordery, S, Guy, R, Delgado-
Charro, M, Pereira de Santana, D & Bastos Leal, L 2018, 'Topical bio(in)equivalence of metronidazole
formulations in vivo', International Journal of Pharmaceutics, vol. 541, pp. 167-172.
https://doi.org/10.1016/j.ijpharm.2018.02.032
DOI:
10.1016/j.ijpharm.2018.02.032
Publication date:
2018
Document Version
Peer reviewed version
Link to publication
Publisher Rights
CC BY-NC-ND
https://doi.org/10.1016/j.ijpharm.2018.02.032
University of Bath
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 22. May. 2019
 1 
TOPICAL BIO(IN)EQUIVALENCE OF METRONIDAZOLE FORMULATIONS IN VIVO 1 
Thalita Pedon de Araujo1, Isabelle Moura Fittipaldi1, Danilo Cesar Galindo Bedor1,  2 
Maira Ludna Duarte1, Sarah F. Cordery2, Richard H. Guy2, M. Begonã Delgado-Charro2,  3 
Davi Pereira de Santana1 & Leila Bastos Leal1,3 4 
1Universidade Federal de Pernambuco, Departamento de Ciências Farmacêuticas, CEP: 50740-520, 5 
Recife-PE, Brazil. 6 
2University of Bath, Department of Pharmacy & Pharmacology, Claverton Down, Bath, BA2 7AY, 7 
U.K. 8 
3Correspondence: leila.leal@nudfac.com.br, tel. +55.994516044  9 
 10 
 11 
Graphical abstract 12 
  13 
  14 
 2 
ABSTRACT 15 
The topical bioavailabilities of metronidazole from a commercially available ‘reference’ product 16 
(Rozex®) and two extemporaneous test formulations were compared.  With the reference drug product, 17 
a full skin pharmacokinetic profile, in vivo in human volunteers (following a 6-hour uptake and 18 
clearance over the subsequent 22 hours), was obtained using an improved stratum corneum (SC) 19 
sampling procedure.  Then, a two-time point SC sampling method enabled the bio(in)equivalence of 20 
the test formulations to Rozex® to be evaluated. One test formulation was shown to be bioequivalent 21 
to Rozex®, both for uptake and clearance, whereas the other (more viscous and less spreadable) 22 
formulation was not.  The delivery of metronidazole into the underlying viable epidermal tissue from 23 
Rozex® and from the equivalent test formulation was 2.5 to 3.5-fold higher than that from the 24 
inequivalent extemporaneous vehicle.  The results highlight that the quantitative composition of a 25 
formulation, as well as its physical properties that influence events that take place at the vehicle-skin 26 
interface, can have a dramatic impact on the delivery of drug into the SC and subsequently to the viable 27 
skin layers below.  The reproducible, sensitive and facile in vivo methodology employed may prove 28 
of particular value where regulatory approval of generic formulations lacks objective rigour. 29 
 30 
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1. Introduction 35 
The development of methodology, both in vivo and in vitro, to determine the bioavailability of topically 36 
applied drugs, the site of action of which is on or within (or even just below) the skin, is the subject of 37 
considerable attention at the present time (Yacobi, et al., 2014). A particular driving force for this level 38 
of interest is to establish reliable and validated approaches to assess the bioequivalence between topical 39 
drug products so that less expensive generic formulations can gain regulatory approval and lower the 40 
burden on healthcare budgets. 41 
Currently, there is no standardised methodology for topical bioavailability or bioequivalence 42 
measurement, and different regulations apply in different countries.  Most typically, the approaches 43 
adopted by the U.S. Food & Drug Administration (FDA) are dominant and are followed by other 44 
agencies such as the European Medicines Agency (EMA) and the U.K. Medicines and Healthcare 45 
products Regulatory Agency (MHRA).  Specifically, in the majority of cases, clinical studies, which 46 
are usually expensive, prolonged and poorly discriminating, are required to establish bioequivalence 47 
(Shah et al., 1998; Braddy et al., 2015); a particular exception involves corticosteroid formulations, 48 
for which the vasoconstriction assay may be used (US FDA, 1995), and a few other exceptions have 49 
been granted for specific products (e.g., acyclovir ointment, a lidocaine patch and dapsone and 50 
ivermectin products) (Draft Guidance on Acyclovir, 2012; Draft Guidance on Lidocaine patch, 2016; 51 
Draft Guidance on Dapsone, 2017; Draft Guidance on Ivermectin products, 2017).  Other countries 52 
have also adopted FDA standards but some, like Japan and South Africa, have also accepted the 53 
surrogate in vivo technique of stratum corneum (SC) sampling using tape-stripping (Braddy et al., 54 
2015).   In contrast, elsewhere, there exists essentially no requirement for the establishment of in vivo 55 
bioequivalence of topical products. For example, in Brazil, the principal requirements for the 56 
registration of a generic product are (a) pharmaceutical equivalence, and (b) that the composition of 57 
the generic formulation should contain excipients with the same function as those in the reference 58 
product (Brazil, 2011).  59 
In addition to SC sampling, other techniques being examined closely as surrogates (either alone or in 60 
combination) for clinical trials are in vitro skin permeation experiments and in vivo microdialysis, 61 
including open-flow microperfusion (Bodenlenz et al., 2017; Yacobi, et al., 2014).  The former, of 62 
course, has been widely used in product development (both topical and transdermal) for many years 63 
and now seems likely – at least in some form – to be eventually recognised as a regulatory tool.   64 
While recent data from open-flow microperfusion experiments appear to indicate a real step-change in 65 
the quality of microdialysis data (Bodenlenz et al., 2017), there remains much to be done before one 66 
can envisage this technically highly-demanding approach as a routine method.    67 
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SC tape-stripping has had a chequered past, an FDA draft guidance having been withdrawn relatively 68 
quickly after its publication because of inconsistency in the results from two very qualified laboratories 69 
(US FDA, 1998).  Further, despite a clear diagnosis and understanding of why this happened, in 70 
addition to well-supported demonstrations of the usefulness of an improved protocol (N’Dri-Stempfer 71 
et al., 2009) to distinguish bio(in)equivalence between anti-fungal (econazole) and non-steroidal anti-72 
inflammatory (diclofenac) formulations (Cordery et al., 2017), the SC sampling method has yet to 73 
regain the confidence of the FDA, or of those regulatory agencies which follow its lead.   74 
Nevertheless, the SC represents an accessible and easily interrogated skin compartment in vivo.  The 75 
recent results from the diclofenac study (Cordery et al., 2017), and their correlation with in vitro skin 76 
penetration data, demonstrate that the technique also has value for assessing the bioavailability of drugs 77 
with sites of action not only in the SC (such as econazole (N’Dri-Stempfer et al., 2009)), but in skin 78 
layers below the barrier as well.  For this reason, the improved tape-stripping method (N’Dri-Stempfer 79 
et al., 2009) has been used in the research reported here which aimed to evaluate the bioequivalence 80 
(or not) of two extemporaneous metronidazole formulations to the marketed Rozex® product, the only 81 
topical formulation of this drug available in many countries (including Brazil).  The ‘generic’ 82 
formulations contained the same concentration of metronidazole and the same excipients, but differed 83 
in their spreadabilities and viscosities from Rozex®.  It follows that, in terms of the FDA’s definitions 84 
(Chang et al., 2013), the test formulations were Q1 (having the same components) with Rozex®, but 85 
not Q2 (i.e., same amounts of the same components) or Q3 (same amounts of the same components 86 
arranged in the same way). 87 
  88 
 5 
2. Materials and methods 89 
2.1 Human subjects 90 
28 healthy volunteers, 19 females and 9 males, participated in the study. The mean (range) age, weight, 91 
and height of the subjects were 24 (21-32) years; 62.2 (53-78) kg; and 165 (156–175) cm, respectively. 92 
The study protocol (CAAE 34657814.2.0000.5208) was approved by the local ethics committee of the 93 
Universidade Federal de Pernambuco, Recife, Brazil. The subjects provided their informed consent 94 
prior to participating in the study. 95 
2.2 Materials  96 
Metronidazole was from Hubei Hongyuan Pharmaceutical, Hong Kong, China; Rozex® was purchased 97 
from Laboratoires Galderma, Alby-sur-Chéran - France; sodium hydroxide and methyl and propyl 98 
parabens were acquired from Vetec, Rio de Janeiro, Brazil; propylene glycol was obtained from 99 
Henrifarma, São Paulo, Brazil; and Carbopol was purchased from Fagron, Jundia, Brazil.  100 
2.3 Formulations  101 
Two extemporaneous formulations of metronidazole comprising the same drug concentration and the 102 
same excipients as the commercial product (Rozex®) were prepared (Table 1).  The two test 103 
formulations differed only in the quantity of gelling agent used. 104 
 105 
Table 1: Composition (% w/v) of the extemporaneous formulations defined as Test 1 and Test 2. 106 
 107 
Component Test 1 Test 2 
Metronidazole 0.75 0.75 
Propylene glycol 5.0 5.0 
Carbomer 1.0 1.5 
Methyl paraben 0.18 0.18 
Propyl paraben 0.02 0.02 
EDTA 0.05 0.05 
NaOH 20%  qs pH 4.0 qs pH 4.0 
Water  qs 100 qs 100 
 108 
The apparent viscosities of the three formulations were determined on 15 g samples using a concentric 109 
cylinder-type rheometer (MCR 301, Anton Paar Brasil Ltda, Sao Paulo, Brazil) with ASTM spindle 7 110 
at 30 rpm and 25°C.  The spreadability test was performed according to published procedures 111 
(Borghetti et al., 2006). 112 
 113 
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2.4 Stratum corneum (SC) sampling experiments  115 
The principal experimental goal of this work was to determine, using the improved SC tape-stripping 116 
approach (N’Dri-Stempfer et al., 2009), that has been validated for econazole (N’Dri-Stempfer et al., 117 
2009) and, more recently, diclofenac (Cordery et al., 2017), whether the two extemporaneous 118 
metronidazole test formulations were equivalent to Rozex®.  The new protocol calls for an assessment 119 
of equivalence to be made at one so-called ‘uptake’ time, and one so-called ‘clearance’ time, a much 120 
less labour-intensive method than that initially proposed in the now-withdrawn FDA draft guidance 121 
(US FDA, 1998). 122 
To select the most appropriate uptake and clearance times, a preliminary study was first performed to 123 
measure drug levels in the SC after a series of different uptake times (1, 2, 4 and 6 hours), and a series 124 
of clearance times (2, 6, 11, 14, 18 and 22 hours) post-removal of the Rozex® formulation.  These 125 
experiments were conducted (on each of the 14 volunteers) following exactly the method of N’Dri-126 
Stempfer et al. (N’Dri-Stempfer et al., 2009)  with the five specific refinements designed to 127 
significantly improve the quality and reproducibility of the data obtained: (a) a rigorous cleaning of 128 
excess drug product from the application site at the end of the uptake period; (b) retaining the quantity 129 
of drug recovered in the first two tape-strips as material that had been taken up and would ultimately 130 
become available in the underlying skin; (c) increasing the number of tape-strips removed to ensure 131 
collection of most (> 75%) of the SC; (d) controlling the tape-stripped skin area to avoid ‘edge’ effects 132 
and lateral spread of formulation (N’Dri-Stempfer et al., 2009); and (e) combining tape-strips into 133 
groups for drug extraction and subsequent analysis to enhance quantitation. 134 
The ventral forearms of the volunteers were first washed with water and gently dried with paper towels.  135 
Thirty minutes later, the Rozex® formulation was applied to 10 sites distributed over the two arms (one 136 
each for the four uptake times and the six clearance times); another untreated site was also delineated 137 
on each arm for tape-stripping to provide an analytical control.   Each treated site (2.54 cm2 in area) 138 
was demarcated with a circular template (Scotch Book Tape, 3M Co., St. Paul, MN, USA), and 143.5 139 
mg of Rozex® (i.e., 56.5 mg/cm2) was applied, achieving an even and complete coverage of the skin 140 
with the formulation.  The sites were then occluded with a 4.9 cm2 plastic chamber (Hill Top Research, 141 
Inc., Ohio, USA) to prevent any loss of the formulation from the skin surface.  At each of the designated 142 
uptake times (1, 2, 4 and 6 hours), one plastic chamber was removed and the site cleaned of residual 143 
formulation with two isopropanol wipes (Biosoma® Laboratorios, São Paulo, Brazil).  A smaller 144 
template (1.77 cm2) was then centered over the treated area and the SC was then repeatedly tape-145 
stripped (Scotch Book Tape).  A maximum of 30 tape-strips were taken during which regular 146 
measurements of transepidermal water loss (TEWL) (Tewameter, Courage & Khazaka GmbH,  147 
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Cologne, Germany) were recorded to assess the fraction of SC that had been removed.  If TEWL 148 
reached more than 6-times the value observed before tape-stripping commenced, no more SC was 149 
removed as the barrier had by then been reduced to less than 25% of its normal function (Kalia et al., 150 
1996; 2000). 151 
Further, at 6 hours, all of the ‘clearance’ sites were exposed and subjected to the same cleaning 152 
procedure as described above. The skin sites were then left open to the ambient conditions before being 153 
successively tape-stripped at 2, 6, 11, 14, 18 and 22 hours later.   154 
Having conducted this preliminary set of experiments, the bioequivalence protocol was then performed 155 
on Rozex® and the two test formulations using 6 hours for both the uptake and clearance times.  In this 156 
case, after cleaning the volunteers’ forearms, formulations were applied to 12 treatment sites (3 157 
formulations per subject, and duplicate applications of each formulation on opposite arms); for each 158 
volunteer, on one ventral forearm, the 6 uptake sites to which the formulations were to be applied were 159 
randomly assigned between the wrist and the elbow fold; the 6 clearance sites on the opposite arm 160 
mirrored those used for uptake in each volunteer.  An untreated site was again tape-stripped to provide 161 
an analytical control.  Application and removal of the formulations, and the tape-stripping procedures, 162 
followed exactly the protocol described above except that only one uptake time (6 hours) and one 163 
clearance time (6 hours) were considered.  Quantitative data on the number of tape-strips removed in 164 
the uptake and clearance ‘arms’ of the study are in Supplementary information, Table S1.  Before any 165 
tape-stripping in the bioequivalence study, the volunteers were asked to report any adverse effects that 166 
they may have experienced, and the treated skin sites were inspected visually by the investigators. 167 
2.5 Metronidazole extraction and analysis 168 
The drug was extracted from tapes 1 to 14 individually by shaking with 1 mL of acetonitrile in a closed 169 
vial for 6 hours; tapes 15-17, 18-20, 21-23, 24-26 and 27-30 were grouped for extraction, and drug 170 
was extracted therefrom in the same way.  Following filtration, the extraction samples were analysed 171 
for metronidazole with a previously validated high-performance liquid chromatography method with 172 
UV detection at 320 nm (Shimadzu Corp. (Kyoto, Japan) (Melo, et al. 2016). Separation was 173 
performed on a C18 reversed-phase column 150 x 4.60mm and a C18 (5µm) pre-column 4 x 4 mm (5 174 
µm) (Shimadzu Corp.) at 35°C. The mobile phase was an 88:12 mixture of 20 mM monobasic sodium 175 
phosphate buffer at pH 3.0 and acetonitrile; the flow rate was 1 mL/min, the injection volume 20 µL.  176 
2.6 Interpretation of results 177 
A non-compartmental analysis method was used to analyse the results from the preliminary SC 178 
sampling experiments (Phoenix WinNonlin Professional version 5.0, Certara, Princeton, NJ, USA).  179 
From the profiles of the quantity of metronidazole in the SC as a function of time, the following 180 
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‘conventional’ pharmacokinetic parameters were determined: (a) The maximum quantity of drug in 181 
the SC (Amax) was directly observed from the data.  (b) The rate constant describing metronidazole 182 
elimination from the SC (ke) was determined from the slope of the linear regression of the ‘clearance’ 183 
phase of the log-transformed drug quantity versus time profile; the corresponding elimination half-life 184 
was found from t1/2 = ln 2/ke.  (c)  The area under the SC quantity of drug profile as a function of time 185 
(AUC0-∞) was calculated using the trapezoidal method for that portion up to the last measured value 186 
(At) and the standard extrapolation for that part from the final measurement to t = ∞, i.e., AUC0-∞ = 187 
AUC0-t + At/ke.   188 
Analysis of the results from the bioequivalence protocol followed the published approach of N’Dri-189 
Stempfer et al. (2008); briefly, a test formulation (Test 1 or Test 2) was considered bioequivalent to 190 
the reference Rozex® product if the ratio (± the 90% confidence interval) of the amount of drug in the 191 
SC from the test product to that from the reference formulation was within the range of 0.8 to 1.25.  192 
Determinations of bioequivalence (or not) were performed using (i) the drug amount in the SC after 193 
the 6-hour uptake period, and (ii) the quantity of metronidazole in the SC following the subsequent 6 194 
hours of clearance.  Although the sum of the SC levels determined in uptake and clearance has also 195 
been reported as an additional metric in previous work (N’Dri-Stempfer et al., 2008), there appears to 196 
be no clear mechanistic justification for doing so and such calculations have not been performed on 197 
the data obtained in this study. 198 
  199 
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3. Results 200 
3.1 Formulation characteristics 201 
The measured physical properties of the test and reference (Rozex®) formulations are in Table 2. 202 
Table 2: Physical characteristics of the test and reference formulations studied (mean ± S.D.; n = 6) 203 
Formulation Test 1 Rozex® Test 2 
pH 4.40 ± 0.03 4.59 ± 0.05 4.15 ± 0.07 
Viscosity (Pa.s) 19.9 ± 0.33 22.2 ± 0.40 28.8 ± 0.63 
Spreadability (cm2) 4.03 ± 0.12 2.59 ± 0.02 0.78 ± 0.07 
The two test formulations differed only in the quantity of gelling agent; that is, the products could be 204 
considered, using the U.S. F.D.A terminology, as Q1 equivalent (same components), but Q2 205 
inequivalent (same components but not in the same quantities).  The higher quantity of Carbomer in 206 
Test 2 led to a more viscous and less spreadable formulation than Test 1; the values for the two test 207 
vehicles bracketed those of the reference product. 208 
3.2 In vivo tolerability 209 
The distribution of skin types amongst the volunteers was: 3 of type II, 4 type III, 4 type IV and 3 type 210 
V.  After 6-hour exposure to the formulations, no visible signs of irritation were observed in any 211 
volunteer.  Similarly, at the ‘clearance’ sites, no redness at the treated skin sites had developed before 212 
SC sampling.  Post-tape-stripping at both uptake and clearance sites, the skin was visibly irritated.  213 
However, the intensity of the reaction was no different at the control, untreated tape-stripped sites.  214 
Nonetheless, all volunteers fully completed the experiment. 215 
3.3 SC sampling in vivo: pharmacokinetic profile and bioequivalence assessment 216 
The results of the preliminary series of experiments are summarized in Figure 1, which presents the 217 
average profile (derived from 14 subjects) of the quantity of metronidazole in the SC as a function of 218 
time over 28 hours.  In this period, drug uptake was measured at 4 times over the first 6 hours and drug 219 
clearance was determined on 6 occasions over the subsequent 22 hours.  As expected, the maximum 220 
amount of drug found in the SC (Amax) was achieved after the longest uptake time (i.e., 6 hours); the 221 
mean (± S.D) value of Amax was 27.7 (±10.1) µg/cm2.  Assuming a first-order clearance of 222 
metronidazole from the SC after the longest uptake time of 6 hours, linear regression of the log-223 
transformed drug quantity versus time profile between 6 and 28 hours yields the average (± S.D, n = 224 
14) value for the elimination rate constant (ke) of 0.14 (±0.03) h-1; the corresponding half-life is 225 
therefore 5.1 (± 1.0) hours.  The average r2 value of the 14 log-linear regressions was 0.90 with a 226 
standard deviation of 0.04.  The mean (± S.D) measured area under the SC amount of drug vs. time 227 
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profile (AUC0-28h) was 288 (±133) (µg•h)/cm2 and, using the calculated ke, AUC0-∞ was determined to 228 
be 299 (±135) (µg•h)/cm2. 229 
Figure 1: Kinetic profile of the quantity of metronidazole in the stratum corneum in vivo during uptake (t ≤ 6 230 
hr) and clearance (t ≥ 6 hr) phases following topical application of Rozex®. Each data point represents the 231 
mean (± S.D.) value from 14 volunteers. 232 
 233 
The results of the subsequent bioequivalence protocol are summarised in Table 3 and Figure 2.  An 234 
analysis of variance followed by multiple comparison tests when appropriate indicates clearly that, 235 
while the average values of drug quantities in the SC (both in uptake and clearance) are not 236 
significantly different between the reference product and formulation Test 1, there is a significant 237 
difference between the reference and formulation Test 2.  However, the ratios of drug amount in the 238 
SC in clearance to that in uptake did not differ significantly between the formulations. 239 
When the ratio of drug quantity in the SC following application of a test formulation to that after 240 
treatment with the reference product is determined during uptake and clearance, the results expressed 241 
as the mean values and the 90% confidence intervals are as shown in Figure 3.  Traditionally, as used 242 
by the US FDA, for example, the average ratio and the 90% confidence limits must fall within the 243 
range 0.8 – 1.25 for a generic product to be considered equivalent to the reference (US FDA, 2007).  244 
It follows from the results in Figure 3, therefore, that formulation Test 1 was found to be bioequivalent 245 
from the data for uptake and for clearance.  In contrast, formulation Test 2 was clearly inequivalent for 246 
uptake and clearance. 247 
  248 
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Table 3:  Results of the two-point SC sampling bioequivalence protocol in vivo.  The amounts of metronidazole 249 
measured in the SC (geometric mean, and 90% confidence interval (C.I.); n = 14) during uptake and clearance, 250 
together with the corresponding ratios of clearance-to-uptake for the reference and two test products tested.   251 
 252 
 253 
 254 
 255 
 256 
 257 
Figure 2: The quantities of metronidazole measured in the SC (mean ± the upper and lower 90% confidence 258 
interval; n = 14) during uptake and clearance following application of the reference and test formulations. 259 
 260 
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Average 0.60 0.57 0.70 
Lower 90% C.I. 0.48 0.46 0.57 
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Figure 3:  Bioequivalence assessment of the extemporaneous gels compared with the reference listed product 263 
(Rozex®).  The ratios (mean ± the upper and lower 90% confidence interval; n = 14) were determined using the 264 
quantities of drug in the SC during uptake and clearance.  The 0.8 to 1.25 range for the ratio, for which 265 
bioequivalence is implied, are indicated on the graph. 266 
 267 
 268 
 269 
  270 
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4. Discussion 271 
Measurement of the physical characteristics of the two test formulations confirms that their Q2 272 
inequivalence to Rozex® translates into evidence of Q3 inequivalence as well.  A one-way analysis of 273 
variance followed by Tukey’s multiple comparison test reveals that the pH, viscosity and spreadability 274 
values of each of the two test formulations differ significantly (p < 0.05) from each other and from 275 
those of Rozex®, the reference product. 276 
The preliminary SC sampling protocol produced a classic pharmacokinetic profile that adequately 277 
characterised the uptake and ‘clearance’ of metronidazole from this skin compartment after application 278 
of Rozex®.  This type of information, derived using the improved and previously validated SC 279 
sampling methodology (N’Dri-Stempfer et al., 2008), was effectively the intention of the original 280 
F.D.A. draft guidance on ‘dermatopharmacokinetics’ (or DPK) (US FDA, 1998).  Clearly, however, 281 
with respect to using the approach for the assessment of bio(in)equivalence between different 282 
formulations, the protocol is extremely labour-intensive in terms of the sample handling and analytical 283 
chemistry involved (Pershing et al., 2001).  284 
It was for this reason that the simplified two-time point method was developed and successfully applied 285 
to the comparison of three econazole formulations (N’Dri-Stempfer et al., 2009).  In the 286 
bioequivalence set of experiments reported here, this protocol (using uptake and clearance times of 6 287 
hours) again generated reproducible data and differentiated between Rozex® and the two test 288 
formulations with a modest number (i.e., 14) of subjects (Table 3 and Figure 2). 289 
First of all, the clearance/uptake ratios across the three formulations were consistently around 0.6 (and 290 
not statistically different from one another) suggesting that the chosen timings for the two SC sampling 291 
events were well-chosen based on the preliminary experiment (Figure 1); that is, the uptake time 292 
ensured a significant presence of metronidazole in the SC after 6 hours, while the 6-hour clearance 293 
was sufficient for the drug level to have measurably decreased (by nearly 50%, consistent with the 294 
results from the preliminary experiment) but yet still be present in an amount well above the analytical 295 
limit of quantification.  Furthermore, it has been shown that the {log(clearance/uptake ratio)} is 296 
proportional to the lag time for clearance (N’Dri-Stempfer et al. 2008, 2009).  Therefore, the fact that 297 
the clearance/uptake ratios were essentially identical for the three products (as shown in Figure 4) 298 
indicates that the clearance rate constant from the SC is the same (i.e., the lag time and drug diffusion 299 
rates are similar).   300 
 301 
 302 
 303 
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Figure 4.  Clearance-to-uptake ratios (stippled bars, left-hand axis; mean ± the upper and lower 90% 304 
confidence interval; n = 14) of metronidazole delivered into the skin from reference and two test formulations; 305 
and the corresponding estimated average fluxes (Jav) of the drug (shaded bars, right-hand axis; mean ± the 306 
upper and lower 90% confidence interval; n = 14) from the SC into the underlying viable skin tissue. 307 
 308 
Second, using the uptake and clearance results, together with the corresponding 90% confidence 309 
intervals, it was then possible to undertake a conventional bioequivalence assessment of the two test 310 
formulations against Rozex® (Figure 3).  It is evident from this analysis that the Test 2 formulation is 311 
inequivalent to the reference product, regardless of whether the evaluation is performed using the 312 
uptake data or the clearance results.  In contrast, the Test 1 formulation was equivalent to Rozex® 313 
based on either uptake or clearance data.   314 
Third, it is apparent that the small difference in composition between the Test 1 and Test 2 formulations 315 
(Table 1) can have a profound effect on topical bioavailability.  Indeed, following the approach 316 
described in a recent publication (Cordery et al., 2017), the uptake and clearance amounts of the drug 317 
in the SC can be used to estimate the average flux (Jav) of metronidazole from the SC into the 318 
underlying viable skin tissue (i.e., the site of action): 319 
Jav = (QUp – QCl)/∆t    (1) 320 
where QUp is the mass per unit area of drug in the SC at the end of the 6-hour uptake period, QCl is the 321 
mass per unit area of metronidazole in the SC 6 hours after removal of the formulation, and ∆t is the 322 
time elapsed between the uptake and clearance measurements (i.e., in this case, 6 hours).  The mean 323 
values (and lower, upper 90% confidence intervals) of Jav for Rozex®, Test 1 and Test 2, calculated 324 
from the data in Table 3, are 1.27 (0.63, 1.92), 1.74 (0.92, 2.55) and 0.51 (0.21, 0.81) µg/cm2/hr, 325 
respectively (Figure 4).  In other words, metronidazole delivery into the viable skin from formulation 326 
Test 1 was >3-fold greater than that from Test 2 (significantly different with p < 0.01), a clear reflection 327 
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of the differential quantities of metronidazole taken up into the SC rather than any difference in drug 328 
diffusion through the barrier (as seen by the consistency of the clearance-to-uptake ratios in Table 3). 329 
In terms of the significance of these findings, perhaps the most important is that, in countries such as 330 
Brazil, the extemporaneous formulations studies here - being Q1 equivalent to Rozex® - would in 331 
theory be approvable generics despite, in the case of Test 2, clear inequivalence in terms of drug 332 
delivery to the skin.  At the very least, therefore, studies such as the one presented here, offer a 333 
relatively straightforward in vivo methodology with which to compare the local bioavailability of a 334 
topical drug administered in a new formulation with that from the reference product. 335 
Finally, it is worth pointing out that this research, like almost all recent efforts to address the issue of 336 
topical bioavailability/bioequivalence, has involved the single application of drug products to the skin.  337 
However, the treatment of major skin diseases involves repeated, chronic dosing and it may be argued, 338 
therefore, that it would be better to assess topical bioavailability/bioequivalence under multidose 339 
conditions (Wagner, 2013).  This is particularly important for formulations which contain excipients 340 
that may exert a cumulative effect on skin barrier function.  Further work designed to examine this 341 
issue in more detail is clearly warranted. 342 
  343 
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5. Conclusions 344 
The delivery of metronidazole into the skin from a commercially available product, and from two 345 
extemporaneous formulations, was assessed by an improved stratum corneum (SC) sampling 346 
procedure in vivo, in healthy human volunteers.  While the components of the three formulations were 347 
the same, the quantitative compositions, as well as their physical characteristics (including viscosity 348 
and spreadability) were different.  It was shown that the uptake and clearance of the drug from one of 349 
the ‘test’ formulations were not significantly different from those of the ‘reference’ product.  In 350 
contrast, the other ‘test’ formulation was clearly inferior to the ‘reference’.  Simple manipulation of 351 
the SC sampling data permitted the flux of metronidazole into the underlying viable skin compartment 352 
to be deduced; consistent with the bioavailability assessment, the rates of drug delivery from the test 353 
formulations were significantly different. 354 
 355 
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Table S1 441 
Number of tape-strips removed in the uptake and clearance ‘arms’ of the bioequivalence protocol. 442 
No.  of  subjects  (N)  and  %  of  subjects  from  whom  less  than  30  tape-­‐strips  were  taken  
in  uptake  and  clearance  ‘arms’  of  the  bioequivalence  study  
     UPTAKE             CLEARANCE            
     T1   REF   T2   T1   REF   T2  
N     4   5   4   8   7   7  
%     29   36   29   57   50   50  
    
    
Individual  no.  of  tape-­‐strips  collected  from  these  individuals  
     UPTAKE             CLEARANCE            
     T1   REF   T2   T1   REF   T2  
     21   22   19   18   17   13  
     23   25   20   17   16   14  
     26   25   24   15   19   19  
     22   23   25   19   20   22  
          19        20   18   18  
                    18   25   15  
                    19   15   22  
                    20            
Mean   23.0   22.8   22.0   18.3   18.6   17.6  
S.D.   2.2   2.5   2.9   1.7   3.3   3.7  
%CV   9.4   10.9   13.4   9.1   17.8   21.0  
In neither uptake nor clearance was there any obvious difference between products in the number of 443 
tape-strips removed for those subjects requiring less than 30 strips to remove the bulk of their stratum 444 
corneum.  Therefore, none of the excipients (alone or in combination) used in the three formulations 445 
are believed to undermine the cohesivity of the skin barrier (as has been reported in other situations – 446 
see, for example, Cordery et al., 2017).  447 
 448 
 449 
